US Stock MarketDetailed Quotes

TRDA Entrada Therapeutics

Watchlist
  • 17.660
  • -0.460-2.54%
Close Dec 13 16:00 ET
  • 17.660
  • 0.0000.00%
Post 16:00 ET
660.84MMarket Cap12.26P/E (TTM)

Entrada Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-55.25%19.57M
421.16%94.69M
134.05%59.12M
129.01M
41.85M
43.74M
18.17M
25.26M
0
0
Operating revenue
-55.25%19.57M
421.16%94.69M
134.05%59.12M
--129.01M
--41.85M
--43.74M
--18.17M
--25.26M
--0
--0
Cost of revenue
Gross profit
Operating expense
38.71%41.23M
19.73%41.27M
22.45%38.01M
35.92%132.18M
44.43%36.94M
14.60%29.72M
46.17%34.47M
40.13%31.04M
90.21%97.25M
38.56%25.58M
Selling and administrative expenses
32.38%9.97M
13.06%9.24M
18.41%9.4M
5.39%32.29M
-12.55%8.65M
7.94%7.53M
11.39%8.17M
23.39%7.94M
101.56%30.64M
62.25%9.89M
-General and administrative expense
32.38%9.97M
13.06%9.24M
18.41%9.4M
5.39%32.29M
-12.55%8.65M
7.94%7.53M
11.39%8.17M
23.39%7.94M
101.56%30.64M
62.25%9.89M
Research and development costs
40.85%31.26M
21.81%32.04M
23.83%28.61M
49.96%99.88M
80.37%28.29M
17.05%22.19M
61.87%26.3M
46.98%23.1M
85.41%66.61M
26.88%15.69M
Operating profit
-254.57%-21.66M
427.77%53.42M
465.28%21.11M
96.75%-3.16M
119.18%4.91M
154.03%14.01M
30.88%-16.3M
73.91%-5.78M
-90.21%-97.25M
-38.56%-25.58M
Net non-operating interest income expense
42.34%5.77M
3.51%4.37M
58.60%4.21M
478.19%15.22M
351.79%4.29M
407.01%4.05M
946.65%4.22M
453.54%2.66M
8,590.32%2.63M
7,207.69%950K
Non-operating interest income
42.34%5.77M
3.51%4.37M
58.60%4.21M
478.19%15.22M
351.79%4.29M
407.01%4.05M
946.65%4.22M
453.54%2.66M
--2.63M
--950K
Other net income (expense)
Income before tax
-187.98%-15.89M
578.35%57.79M
910.98%25.33M
112.74%12.06M
137.34%9.2M
171.86%18.06M
47.88%-12.08M
85.59%-3.12M
-84.95%-94.62M
-33.51%-24.63M
Income tax
89.31%-1.86M
-80.08%2.76M
-48.44%1.83M
18.74M
18.74M
-17.4M
13.85M
3.55M
0
0
Net income
-139.57%-14.03M
312.25%55.03M
452.05%23.5M
92.93%-6.69M
61.25%-9.54M
241.07%35.46M
-11.86%-25.93M
69.20%-6.67M
-84.95%-94.62M
-33.51%-24.63M
Net income continuous Operations
-139.57%-14.03M
312.25%55.03M
452.05%23.5M
92.93%-6.69M
61.25%-9.54M
241.07%35.46M
-11.86%-25.93M
69.20%-6.67M
-84.95%-94.62M
-33.51%-24.63M
Minority interest income
Net income attributable to the parent company
-139.57%-14.03M
312.25%55.03M
452.05%23.5M
92.93%-6.69M
61.25%-9.54M
241.07%35.46M
-11.86%-25.93M
69.20%-6.67M
-84.95%-94.62M
-33.51%-24.63M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-139.57%-14.03M
312.25%55.03M
452.05%23.5M
92.93%-6.69M
61.25%-9.54M
241.07%35.46M
-11.86%-25.93M
69.20%-6.67M
-84.95%-94.62M
-33.51%-24.63M
Basic earnings per share
-132.71%-0.35
306.41%1.61
433.33%0.7
93.38%-0.2
63.29%-0.29
233.75%1.07
-5.41%-0.78
69.57%-0.21
62.99%-3.02
11.24%-0.79
Diluted earnings per share
-134.31%-0.35
298.72%1.55
423.81%0.68
93.38%-0.2
63.29%-0.29
227.50%1.02
-5.41%-0.78
69.57%-0.21
62.99%-3.02
11.24%-0.79
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue -55.25%19.57M421.16%94.69M134.05%59.12M129.01M41.85M43.74M18.17M25.26M00
Operating revenue -55.25%19.57M421.16%94.69M134.05%59.12M--129.01M--41.85M--43.74M--18.17M--25.26M--0--0
Cost of revenue
Gross profit
Operating expense 38.71%41.23M19.73%41.27M22.45%38.01M35.92%132.18M44.43%36.94M14.60%29.72M46.17%34.47M40.13%31.04M90.21%97.25M38.56%25.58M
Selling and administrative expenses 32.38%9.97M13.06%9.24M18.41%9.4M5.39%32.29M-12.55%8.65M7.94%7.53M11.39%8.17M23.39%7.94M101.56%30.64M62.25%9.89M
-General and administrative expense 32.38%9.97M13.06%9.24M18.41%9.4M5.39%32.29M-12.55%8.65M7.94%7.53M11.39%8.17M23.39%7.94M101.56%30.64M62.25%9.89M
Research and development costs 40.85%31.26M21.81%32.04M23.83%28.61M49.96%99.88M80.37%28.29M17.05%22.19M61.87%26.3M46.98%23.1M85.41%66.61M26.88%15.69M
Operating profit -254.57%-21.66M427.77%53.42M465.28%21.11M96.75%-3.16M119.18%4.91M154.03%14.01M30.88%-16.3M73.91%-5.78M-90.21%-97.25M-38.56%-25.58M
Net non-operating interest income expense 42.34%5.77M3.51%4.37M58.60%4.21M478.19%15.22M351.79%4.29M407.01%4.05M946.65%4.22M453.54%2.66M8,590.32%2.63M7,207.69%950K
Non-operating interest income 42.34%5.77M3.51%4.37M58.60%4.21M478.19%15.22M351.79%4.29M407.01%4.05M946.65%4.22M453.54%2.66M--2.63M--950K
Other net income (expense)
Income before tax -187.98%-15.89M578.35%57.79M910.98%25.33M112.74%12.06M137.34%9.2M171.86%18.06M47.88%-12.08M85.59%-3.12M-84.95%-94.62M-33.51%-24.63M
Income tax 89.31%-1.86M-80.08%2.76M-48.44%1.83M18.74M18.74M-17.4M13.85M3.55M00
Net income -139.57%-14.03M312.25%55.03M452.05%23.5M92.93%-6.69M61.25%-9.54M241.07%35.46M-11.86%-25.93M69.20%-6.67M-84.95%-94.62M-33.51%-24.63M
Net income continuous Operations -139.57%-14.03M312.25%55.03M452.05%23.5M92.93%-6.69M61.25%-9.54M241.07%35.46M-11.86%-25.93M69.20%-6.67M-84.95%-94.62M-33.51%-24.63M
Minority interest income
Net income attributable to the parent company -139.57%-14.03M312.25%55.03M452.05%23.5M92.93%-6.69M61.25%-9.54M241.07%35.46M-11.86%-25.93M69.20%-6.67M-84.95%-94.62M-33.51%-24.63M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -139.57%-14.03M312.25%55.03M452.05%23.5M92.93%-6.69M61.25%-9.54M241.07%35.46M-11.86%-25.93M69.20%-6.67M-84.95%-94.62M-33.51%-24.63M
Basic earnings per share -132.71%-0.35306.41%1.61433.33%0.793.38%-0.263.29%-0.29233.75%1.07-5.41%-0.7869.57%-0.2162.99%-3.0211.24%-0.79
Diluted earnings per share -134.31%-0.35298.72%1.55423.81%0.6893.38%-0.263.29%-0.29227.50%1.02-5.41%-0.7869.57%-0.2162.99%-3.0211.24%-0.79
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Tesla
TSLA
+4.34%
MicroStrategy
MSTR
+4.20%
MARA Holdings
MARA
+0.66%
Apple
AAPL
+0.07%
Microsoft
MSFT
-0.51%

Unlock the Full List